Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma

European Journal of Cancer

Volumn 51, Issue 17, 2015, Pages 2580-2586

  Albiges, Laurence ^a,b   Fay, André P ^a   Xie, Wanling ^a   Krajewski, Katherine ^a   McDermott, David F ^c,e   Heng, Daniel Y C ^d   Dariane, Charles ^b   DeVelasco, Guillermo ^a   Lester, Renee ^a   Escudier, Bernard ^b   Choueiri, Toni K ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

mTOR; PD 1; PD L1; Renal cell carcinoma; Targeted therapy; VEGFR

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PROGRAMMED DEATH 1 LIGAND 1; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; TIME TO TREATMENT; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL; KIDNEY NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84948573565     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.08.017     Document Type: Article

References (23)

1. J. Ferlay, I. Soerjomataram, R. Dikshit, and et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012 Int J Cancer 2014
2. L. Albiges, T. Choueiri, B. Escudier, and et al. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer Eur Urol 67 1 2015 100 110
3. D.F. McDermott, and M.B. Atkins PD-1 as a potential target in cancer therapy Cancer Med 2 5 2013 662 673
4. L.C. Harshman, C.G. Drake, and T.K. Choueiri PD-1 blockade in renal cell carcinoma: to equilibrium and beyond Cancer Immunol Res 2 12 2014 1132 1141
5. J.R. Brahmer, C.G. Drake, I. Wollner, and et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 19 2010 3167 3175
6. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
7. C.G. Drake, D.F. McDermott, M. Sznol, and et al. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up J. Clin. Oncol. 31 2013 (suppl; abstr 4514)
8. J.R. Brahmer, S.S. Tykodi, L.Q.M. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 26 2012 2455 2465
9. D.C. Cho, J.A. Sosman, M. Sznol, and et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC) J. Clin. Oncol. 31 2013 (suppl; abstr 4505)
10. D.F. McDermott, M. Sznol, J.A. Sosman, and J.-C. Soria Immune correlates and long term follow up of a phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC) Ann Oncol 2014 Abstract 809O(Suppl)
11. R.S. Herbst, J.-C. Soria, M. Kowanetz, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 7528 2014 563 567
12. R.J. Motzer, B.I. Rini, D.F. McDermott, and et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial J Clin Oncol 2014
13. T.K. Choueiri, M.N. Fishman, B.J. Escudier, and et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial J. Clin. Oncol. 32 2014 5s (suppl; abstr 5012)
14. D.Y.C. Heng, W. Xie, M.M. Regan, and et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 34 2009 5794 5799
15. T.E. Hutson, B. Escudier, E. Esteban, and et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 32 8 2014 760 767
16. R.J. Motzer, B. Escudier, S. Oudard, and et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 18 2010 4256 4265
17. R.J. Motzer, B. Escudier, P. Tomczak, and et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Lancet Oncol 14 6 2013 552 562
18. E. Calvo, B. Escudier, R.J. Motzer, and et al. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study Eur J Cancer 48 3 2012 333 339
19. J.S. Ko, A.H. Zea, B.I. Rini, and et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clin Cancer Res 15 6 2009 2148 2157
20. J. Ozao-Choy, G. Ma, J. Kao, and et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies Cancer Res 69 6 2009 2514 2522
21. H. Xin, C. Zhang, A. Herrmann, Y. Du, R. Figlin, and H. Yu Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells Cancer Res 69 6 2009 2506 2513
22. O. Adotevi, H. Pere, P. Ravel, and et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients J Immunother 33 9 2010 991 998
23. M. Terme, S. Pernot, E. Marcheteau, and et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer Cancer Res 73 2 2013 539 549